EB-203
/ EyebioKorea
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 22, 2024
EB-203-201: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
(clinicaltrials.gov)
- P2 | N=50 | Recruiting | Sponsor: EyebioKorea, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
July 05, 2024
EB-203-201: Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degeneration
(clinicaltrials.gov)
- P2 | N=50 | Not yet recruiting | Sponsor: EyebioKorea, Inc.
New P2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration
February 23, 2023
Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=28 | Completed | Sponsor: EyebioKorea, Inc. | Recruiting ➔ Completed | Trial completion date: May 2023 ➔ Oct 2022
Trial completion • Trial completion date
September 14, 2022
Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=28 | Recruiting | Sponsor: EyebioKorea, Inc.
New P1 trial
1 to 4
Of
4
Go to page
1